


Dr. Reddy's Laboratories – Good Health Can't Wait

 [drreddys.com/who-we-are](https://www.drreddys.com/who-we-are)

We accelerate access to affordable and innovative medicines because Good Health Can't Wait.



Promises


Our five promises clarify what we do, what we offer and the commitments we make to our stakeholders. Our patients trust our medicines. We focus our energies on renewing this trust every day. As we keep the interests of our patients at the centre of all that we do, our promises drive us to reach higher levels of excellence.



Bringing expensive medicines within reach



Addressing unmet patient needs



Helping patients manage disease better



Enabling our partners to ensure our medicines are available where needed



Working with partners to help them succeed



Values

In pursuit of providing affordable and innovative medicines for healthier lives, we will create an environment of innovation and learning while continuously reaching for higher levels of excellence

INTEGRITY AND TRANSPARENCY

We will uphold the highest standards of integrity and transparency in all our transactions.

SAFETY

We are committed to providing safe working environments through continuous improvements in our infrastructure, work practices and behaviours.

QUALITY

We are dedicated to designing quality into our products and processes to delight our stakeholders.

PRODUCTIVITY

We strive to achieve more with less through a culture of innovation, continuous improvement and sustained focus on elimination of waste.

RESPECT FOR THE INDIVIDUAL


We are committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals.

COLLABORATION AND TEAMWORK

We will leverage expertise and resources from across our global network to create greater value for our stakeholders.

SUSTAINABILITY

We will create value for our stakeholders in a manner that respects our natural environment and serves the best interests of the communities in which we live and work.



Delivering good health around the world

Views from the top

Since 1999, Anjum Swaroop, our Chief IP Counsel, has been enabling Dr. Reddy's to take great strides as a responsible multinational pharmaceutical company. A company veteran with a galaxy of experience and a fun, challenging career, Anjum is a passionate advocate of IP as a way of developing

a sustainable business as well as addressing the need for affordable, accessible medicines as quickly as possible. "Innovation sometimes requires one to diverge from conventional strategy and pursue new and different paths," she says.



Adding women's health products to our U.S. portfolio

Pleased to announce that we have acquired the MenoLabs® portfolio of women's health and dietary supplements brands in the U.S.



Creating role models to lead the way to a smarter world

We are gearing up to be future-ready and transform our culture and capability, product quality, process robustness, efficiency and productivity.



Our constant endeavour – Patients first!

Pleased to share that we have entered into a definitive agreement with Nestlé India Limited to form a joint venture company that will bring together the well-known global range of nutritional health solutions as well as vitamin, minerals, herbals and supplements of Nestlé Health Science (NHSc) with the strong and established commercial strengths of Dr. Reddy's in India and other agreed territories.



Leadership


Our company is guided by an able Board of Directors and Management Council that steer our long-term growth strategy and ensure we are aligned to our purpose, promises, values and goals.



MEET OUR LEADERSHIP







“It was a dream. It was not a plan on the drawing board, no. But it was a dream.”

- DR. ANJI REDDY

Scientist, entrepreneur and philanthropist Dr. Kallam Anji Reddy is renowned for his path-breaking contributions to making medicines affordable for patients worldwide. He was extremely passionate about drug discovery, was among the pioneers of the active pharmaceutical ingredients (API) industry in India.

Born in Tadepalli village in Andhra Pradesh, India, to a well-to-do farming family, Dr. Anji Reddy grew up watching his father make herbal pills and distribute them free of charge to those in need. Medicine was in his blood, as was a sense of public service. He was also committed to deep science and innovation, which is reflected in Dr. Reddy's Laboratories' legacy as well as its progressive approach to business.

Having completed his B.Sc. Tech degree at the University Department of Chemical Technology, Mumbai, Dr. Anji Reddy earned a doctorate in Chemical Engineering from the National Chemical Laboratory, Pune. He then worked for six years at the state-owned Indian Drugs and Pharmaceuticals Ltd (IDPL), an experience that stoked his entrepreneurial ambitions.

In 1973, Dr. Anji Reddy left IDPL, and over the course of the next decade, co-founded two bulk drug manufacturing ventures. Then, in 1984, he collaborated with two technocrat-entrepreneurs to establish Dr. Reddy's Laboratories and Cheminor Drugs, another bulk drug manufacturing company.

From the outset, he realised that if medicines had to serve their purpose, they had to be affordable and accessible. Dr. Anji Reddy envisioned bringing molecules to India at a price the common man can afford.

But this was not the only way by which he helped people. From supporting a hospital for the elderly, to setting up the Dr. Reddy's Foundation for Human and Social Development in 1995, Dr. Anji Reddy's philanthropic endeavours are well-documented. In 1997, an article published in a prominent magazine highlighting India's abysmal poverty and a widening wealth gap left a lasting impression on him. He identified the lack of opportunity for livelihoods as a major cause of indigence, and encouraged initiatives that would address this need. Programmes such as the Child and Police Project and Livelihood Advancement Business School thrived under his leadership.

By the 1990s, having established a strong presence in APIs, Indian pharma had started to transition its focus towards formulations and finished dosages. Dr. Reddy's led by Dr. Anji Reddy was a key player in this changing landscape. Going up the value chain and entering large regulated markets such as the U.S. became key strategy pillars.

However, it's his passion for drug discovery that remained his "unfinished agenda". Dr. Anji Reddy believed that identifying unique opportunities is what will distinguish Dr. Reddy's Laboratories as a discovery-led company. And this is precisely what we strive to do as a future-forward business dedicated to meeting patients' unmet needs globally.

Until the end, Dr. Anji Reddy remained true to his passion for drug discovery, to the extent of setting up a separate company using his own funds. It was not only the compulsion of innovation that drove him, but also his conviction that medicines must be affordable.